Compounding Pharmacies Should Expect Greater Scrutiny as Government Healthcare Budgets Get Squeezed

by Blank Rome LLP

As Congress continues to grapple over healthcare reform, there are many uncertainties. However, one thing is clear: as government healthcare funding shrinks, federal and state enforcement agencies will continue to target compounding pharmacies for potential fraud.

Compounded drug use and related government spending, particularly on topical creams and ointments, has skyrocketed. Many argue that drug compounding regulation remains murky, making it too easy to prosecute traditional compounders. Compounding advocates suggest regulation of compounders has been heavy-handed and ignores the multiple benefits associated with compounding. Arguably, these competing tensions have led to ineffective industry regulation. These tensions include:

  1. Who is responsible for regulating the industry? The FDA or State Pharmacy Boards?
  2. Who is considered a compounding pharmacy as opposed to a drug manufacturer?
  3. How can a regulatory scheme walk the fine line between patient safety and patient access to compounded drugs?
  4. Do compounded drugs serve as an effective counterbalance to what many consider out-of-control drug prices?

Addressing these policy issues is beyond the scope of this blog, but what is crystal clear is that compounding pharmacies must remain vigilant to avoid or defend a government enforcement action.

Drug Compounding

Drug compounding usually involves a pharmacist combining, mixing, or altering ingredients of a drug to create a medication tailored to the needs of an individual patient. Compounding can be as simple as a local pharmacy adding a flavor to amoxicillin to make it more palatable for your child, or as complicated as altering the potency of an infused therapy because a patient cannot tolerate a more potent dose. It started out as an independent pharmacy or physician’s office creating customized drug versions for individual patients on a small scale, but has morphed into production on a larger scale less tailored to individual specifics.

Largely unknown to the general public, compounding gained notoriety in 2012 with the news of 64 deaths and another 700 fungal infections resulting from New England Compounding Center’s (“NECC”) production of non-sterile compounded, injectable drugs. It became clear that in that case, the regulatory system had failed. While state regulators had cited NECC previously for multiple regulatory violations, NECC had continued to operate after the citation.

Since 2012, more attention has been focused on bringing this industry into compliance. In July, FDA Commissioner Scott Gottlieb announced recent actions taken by the FDA and regulators including:

  1. Enacting the Drug Quality and Security Act in November 2013;
  2. Inspecting over 400 compounders;
  3. Issuing more than 150 warning letters to compounders for significant regulatory violations;
  4. Referring over 50 inspection findings to state regulators;
  5. Overseeing 125 compounded drug recalls; and
  6. Coordinating civil and criminal enforcement with the Department of Justice.

Skyrocketing Utilization and Reimbursement of Compounded Drugs

Over the past several years, the use and cost of compounded drugs has grown steeply. The private sector and government, at both state and federal levels, have felt the pain.

Medicare Part D Hit Hard

From 2015 to 2016, Medicare Part D saw spending on compounded drugs increase 56%. From 2006 to 2015, the number of Medicare Part D beneficiaries using compounded drugs rose 281% and spending during the same time increased 625%. The fastest-growing compounds were topical pain creams and gels. From 2006 to 2015, Medicare Part D spending for topical compounds rose 3,466%, with the average cost per prescription rising from $40 million to $331 million. The Department of Health and Human Services, Office of Inspector General is reviewing Medicare Part D spending on compounded drugs and expects to issue a report in 2018.


TRICARE may have been the worst hit with these dramatic increases. For the first four months of 2015, TRICARE spent more than $1 billion on compounded drugs. While compounded drugs accounted for only 0.5% of the volume of medications reimbursed, they totaled 20% of the total costs. In May 2015, TRICARE changed its compounded drug reimbursement rules to cover only compounds with FDA-approved ingredients. As a result, TRICARE saw compounded drug claims drop by 74% and compound drug prescriptions went from approximately 105,200 per month to approximately 41,800. This translated into a $10 million per month decrease in spending.

Federal Workers Compensation

The Federal Worker’s Compensation Program (“FWCP”) saw compound spending go from $2.35 million in 2011 to $214 million in 2015. A March 2015 Department of Labor, Office of Inspector General Report suggested that the Postal Service, whose spending is included in the FWCP, had incurred over $81.5 million in excessive compound drug costs, and nearly $4.1 million in excessive administrative fees for past two fiscal years.

Private Insurance and State Programs

Utilization increases have not been limited to federal healthcare programs. Express Scripts reports that, while overall U.S. prescription drug spending increased 13.1% in 2014, compounded drug spending increased as much as 218% over the preceding two years. Increased utilization has caused some states to impose stricter compound drug reimbursement standards. Oklahoma, Texas, and Washington adopted closed drug formularies, while Ohio and Mississippi imposed compound drug reimbursement limits.

The Current Enforcement Climate

Increased utilization coupled with ambiguous regulations has led to regulation through investigation and litigation. FDA inspections of compounders have increased by 129% from 94 in 2014 to 215 in 2015. Between October 2012 and August 2016, FDA enforcement staff obtained four permanent injunctions against compounding pharmacies.

In addition to FDA enforcement, federal prosecutions of compounding pharmacies are on the rise. These include:

July 2017: A Mississippi pharmacist pled guilty to participating in a scheme whereby patients were provided unnecessary compounded drugs. The scheme involved selecting compounded drugs based on profitability, as opposed to what patients needed or what was most effective. The scheme is alleged to have involved $192 million in fraudulent claims submitted to TRICARE.

July 2017: A False Claims Act case is pending against Florida Pharmacy Solutions, five other compounding pharmacies, and numerous marketing companies, physicians, and nurses. The suit alleges a nationwide scheme to defraud TRICARE of hundreds of millions of dollars to submit fraudulently inflated reimbursement claims to the government by recruiting beneficiaries to sign up for compounded drugs that were loaded with expensive and medically unnecessary ingredients.

July 2017: The federal government intervened in a False Claims Act case against a Tampa, Florida, compounding pharmacy, alleging that the pharmacy charged government healthcare plans 2,000% to 2,100% more for compounded drugs than it charged cash customers.

June 2017: The owner and head pharmacist of previously discussed NECC was convicted of racketeering, racketeering conspiracy, mail fraud, and introduction of misbranded drugs into interstate commerce with the intent to defraud and mislead. He will serve nine years in prison.

May 2017: Six individuals pled guilty to a health insurance scheme which paid illegal kickbacks to doctors for writing compounded drug prescriptions, supplied pre-printed prescription pads to doctors, and used mass-marketing techniques and call centers to solicit patients. The individuals were sentenced to between two and five years in prison, forfeited more than $30 million in assets, and were ordered to pay more than $130 million in restitution.

March 2017: Eight individuals were charged in a $158 million healthcare fraud scheme involving the submission of fraudulent claims for compounded drugs. The individuals obtained control of a compounding pharmacy and submitted claims to the Department of Labor, Office of Workers’ Compensation obtaining reimbursement rates of up to $28,000 per container for compounded creams. The individuals are alleged to have made illegal payments in the form of promissory notes, free rent, and other inducements to physicians to refer patients, provided pre-printed prescription pads, and contacted patients to request refills from their doctors when not necessary.

These prosecutions cover a broad range of issues:

  • overbilling;
  • automatically refilling prescriptions without consent;
  • creating products with little or no medical value;
  • large-scale production without individual patient prescriptions;
  • using ingredients in compounds that have not been approved for use in the United States; and
  • creating copies of FDA-approved drugs.

As a result, compounding pharmacies should focus their resources on compliance.

Compounders Must Stay Vigilant

Drug compounders should take steps to lessen the likelihood of being investigated and/or becoming the subject of a prosecution:

  1. Review the prescriptions you are filling for high volumes from one doctor or practice.
  2. Review prescriptions for evidence of medical necessity.
  3. Review your expense reimbursement policy and prohibition on gifts and gratuities policies to ensure doctors are not receiving anything of value from your pharmacy in exchange for writing prescriptions.
  4. Avoid indicia of mass production and mass marketing of compounded drugs. These indicia include mass production with bulk ingredients, mass-marketing techniques, using call centers, and providing physicians with pre-printed prescription pads.
  5. Consistently collect patient copayments to avoid unnecessary prescriptions and defaulting to higher priced compounded drugs.
  6. Monitor public and private insurance claims for consistency. Public and private claims should seek the same amount for the same prescription. Further, insurance claims and cash payers should pay the same amount for the same prescription.
  7. Dispense the same or similar compounded drugs to patients with public and private insurance and cash payers. For example, do not simply change the name of a compounded drug and charge private or public insurance more as compared to the amount cash payers are charged for the same drug albeit with a different name.
  8. Do not use intermediate pharmacies which hide or disguise the identity of the compounding pharmacy.
  9. Monitor out-of-state prescriptions filled by your pharmacy. While not improper per se, many investigations and prosecutions involve compounding pharmacies filling a large percentage of out-of-state prescriptions.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Blank Rome LLP | Attorney Advertising

Written by:

Blank Rome LLP

Blank Rome LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.